Victoria Johnson

Stone discussed findings from the first randomized, double-blind, placebo-controlled trial for IgG4-related disease.

People who used GC for over 2 years and 3 years had elevated risks of CVD and infection-related mortality, respectively, that never returned to pre-GC use levels.

IL-18 levels were consistently lower across participants with different SARDs, remission status, and COVID-19 disease characteristics.

While an effective and promising strategy for chronic pain relief, more research on long-term cannabis usage is needed.

People with diabetes, kidney stones, damaged joints, high uric acids, and daily use of NSAID were more likely to develop CKD than others.

People that reported only some or none of their flares had almost twice the rate of gout flares in the last year than those reporting all of their flares.

Highest responders on DAS28 also had significantly greater decreases in 12-hydroxyeicosatetraenoic than low responders.

Combining interventions yielded no significant differences in outcomes, pain, or quality-of-life.

Veterans residing in rural areas were only 10% more likely to initiate biologic therapies than those residing in rural areas.

The pain reduction effects did not last long beyond the scope of the trial, underscoring the importance of continuing such exercises.

SGLT-2 inhibitors had more protective effects than GLP-1 receptor agonists or DPP-4 inhibitors in this population.

A new cohort study including over 6 million participants has found an increased likelihood of Behçet disease, alocpecia, bulbous pemphigoid and other disorders post-COVID infection.

The international phase 4 MOSAIC study is the first evaluating PsAMRIS and MRI-WIPE outcomes in patients with psoriatic arthritis.

Week 156 efficacy and safety data from the FINCH 4 study are consistent with that seen in FINCH 1, 2, and 3.

The rheumatology month in review emphasizes new data on secukinumab, gout clinical decision making, and addressing sleep issues in fibromyalgia.

SF-36v2 scores also improved by 12 points with semaglutide compared with 6.5 points with placebo.

Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.

Abdellatif discussed the importance of screening for osteopenia in patients with severe kidney disease.

Patients exposed to screening were also more likely to receive vaccinations and consult a cardiologist and/or a pneumologist.

Investigators analyzed antibody response after 2 SARS-CoV-2 vaccinations.

The treatment did seem to blunt the glycemic response and influence some inflammatory cytokines.

The ER fluticasone propionate intra-articular injection significantly reduced pain compared with control for up to 14 weeks.

The study also identified a tendency for more prevalent human herpesvirus 6B in people with FM than in those without.

Adherence to a preventative, favorable lifestyle significantly reduced CVD risk in participants with high and low genetic risk.

Two pivotal phase 3 studies previously met their endpoints of significantly reducting daily pain compared with placebo.

The new administration options allow a single-injection option for patients that require a 320 mg dose.

Of patients randomized to guselkumab Q8W, 93% to 99% maintained minimally clinically important improvements in joint disease through 1 year.

Over 70% of participants with MSK pain after COVID-19 fulfilled ACR fibromyalgia criteria in new research.

Calabrese discussed considerations for patients with rheumatic disease diagnosed with COVID-19 and the virus’s role in promoting inflammation.

A comprehensive model of clinical and radiomic features was more accurate in distinguishing flares than either model alone.